EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neonatal screening for isovaleric aciduria: Reducing the increasingly high false‐positive rate in Germany

Simona Murko iD, Asra Dadkhah Aseman, Friederike Reinhardt, Gwendolyn Gramer, Jürgen Günther Okun, Ulrike Mütze, René Santer

JIMD Reports · 2023-01 · 64 (1) · 114-120

DOI: 10.1002/jmd2.12345 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 28.10.2022. Verfasst von Simona Murko und 6 weiteren Autor:innen. Beteiligte Einrichtung: Newborn Screening and Metabolic Laboratory, Department of Pediatrics University Medical Center Eppendorf Hamburg Germany. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Newborn screening (NBS) for isovaleric acidemia (IVA) is performed by flow injection tandem mass spectrometry quantifying C5 carnitines (C5). Isovalerylcarnitine, however, is isomeric with pivaloylcarnitine which can be present in blood due to maternal use of pivaloylester‐containing antibiotics, available in Germany since late 2016. During a 36‐month period (January 19–December 21), all newborns screened in Hamburg with a C5 above cutoff (NeoGram®: 0.50 μmol/L or Neobase®2: 0.45 μmol/L) were included in the study. As a second‐tier test, a simple ultra performance liquid chromatography‐tandem mass spectrometry (UPLC‐MS/MS) method was developed to differentiate the C5 isomers pivaloyl‐, 2‐methylbutyryl‐, isovaleryl‐, and valerylcarnitine. Out of 156 772 newborns tested, one turned out to have genetically proven IVA while 99 were false positive (C5: 0.5–8.2 μmol/L) due to the presence of pivaloylcarnitine. These cases have increased year by year and show local clusters. Retrospective analysis of another 39 cases from 287 206 neonates tested at the NBS center in Heidelberg with C5 elevation (0.9–10.6 μmol/L) but clinical and biochemical exclusion of IVA yielded evidence of pivaloylcarnitine in all cases. Inclusion of a second‐tier test into NBS significantly reduces the high and increasing false‐positive rate of IVA screening. This avoids further diagnostic steps, prevents unnecessary stress and anxiety of parents in a remarkably high number of cases. If Hamburg data of 2021 are extrapolated to all of Germany, one can assume around 800 (1‰) false‐positive cases in comparison to an average of two classic IVA cases per year. Unless licensing of pivaloylester‐containing drugs for use during pregnancy is reconsidered, a second‐tier test for C5 determination is indispensable.

Schlagwörter

Stichwörter der Autor:innen

IVAUPLC‐MS/MSisovaleric acidurianewborn screeningpivaloylcarnitinesecond‐tier

Autor:innen und Institutionen

  • Newborn Screening and Metabolic Laboratory, Department of Pediatrics University Medical Center Eppendorf Hamburg Germany.
  • Division of Child Neurology and Metabolic Medicine, Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg University Hospital Heidelberg Germany.

ORCID-Profile: Simona Murko

Zitieren

APA

Murko, S., Aseman, A. D., Reinhardt, F., Gramer, G., Okun, J. G., Mütze, U., & Santer, R. (2023). Neonatal screening for isovaleric aciduria: Reducing the increasingly high false‐positive rate in Germany. JIMD Reports, 64(1), 114-120. https://doi.org/10.1002/jmd2.12345

Vancouver

Murko S, Aseman AD, Reinhardt F, Gramer G, Okun JG, Mütze U, et al. Neonatal screening for isovaleric aciduria: Reducing the increasingly high false‐positive rate in Germany. JIMD Reports. 2023;64(1):114-120. doi:10.1002/jmd2.12345

BibTeX
@article{Murko2023,
  author = {Murko, Simona and Aseman, Asra Dadkhah and Reinhardt, Friederike and Gramer, Gwendolyn and Okun, Jürgen Günther and Mütze, Ulrike and Santer, René},
  title = {Neonatal screening for isovaleric aciduria: Reducing the increasingly high false‐positive rate in Germany},
  journal = {JIMD Reports},
  year = {2023},
  volume = {64},
  number = {1},
  pages = {114--120},
  doi = {10.1002/jmd2.12345}
}
Kostenlos starten →